ZBH: Other company developments

Item 8.01 Other Events. Zimmer Biomet Holdings, Inc. (“we,” “us,” “our,” the “Company” and other similar words) is filing this Current Report on Form 8-K, including Exhibit 99.1, solely to recast certain financial information and related disclosures included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 20, 2026 (the “2025 Form 10-K”). In the quarter ended March 31, 2026, the responsibilities of certain senior leaders who report to our chief operating decision maker (“CODM”) and the related operating profit information that these leaders present to the CODM changed. The changes were primarily that: 1) results related to our Foot and Ankle business in Europe, Middle East and Africa and Asia Pacific are now included in the results of the Americas operating segment, and 2) certain product category expenses, such as centralized research and development and global marketing, are now included in the results of the Americas operating segment. This Current Report on Form 8-K is being filed solely to recast financial information and related disclosures contained in the 2025 Form 10-K to reflect changes to the composition of our operating segments. The following items of the 2025 Form 10-K are being recast as reflected in Exhibit 99.1 to this Current Report on Form 8-K: • Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations; and • Part II, Item 8. Financial Statements and Supplementary Data. Except as specifically set forth in Exhibit 99.1 to reflect the changes to the composition of our operating segments, no revisions have been made to the 2025 Form 10-K to update for other information, development